Explore

Trendline Trendline
GSK Awaits FDA Decision on Innovative Chronic Hepatitis B Drug

GSK Awaits FDA Decision on Innovative Chronic Hepatitis B Drug

GSK Awaits FDA Decision on Innovative Chronic Hepatitis B Drug
Rapid Read Rapid Read
Affinia Therapeutics to Present Gene Therapy Data for Cardiomyopathy at ASGCT Meeting

Affinia Therapeutics to Present Gene Therapy Data for Cardiomyopathy at ASGCT Meeting

Affinia Therapeutics is set to present new preclinical data on its lead program, AFTX-201, at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting. AFTX-201 is an investigational genetic medicine targeting BAG3-associated dilated cardiomyopathy (DCM). The company will highlight the design of the Phase 1/2 UPBEAT clinical trial, which evaluates the safety and efficacy of AFTX-201. The U.S. FDA has granted Fast Track designation for AFTX-201, and the European Medicines Agency has given it Orphan Drug designation.
Trendline Trendline
Alterity Therapeutics Advances Towards Phase 3 Trial for MSA Treatment

Alterity Therapeutics Advances Towards Phase 3 Trial for MSA Treatment

Alterity Therapeutics Advances Towards Phase 3 Trial for MSA Treatment
Trendline Trendline
Veradermics Announces Conference Call to Discuss Phase 2/3 Study Results for Hair Loss Treatment

Veradermics Announces Conference Call to Discuss Phase 2/3 Study Results for Hair Loss Treatment

Veradermics Announces Conference Call to Discuss Phase 2/3 Study Results for Hair Loss Treatment
Trendline Trendline
Gene Therapy Leaders Explore Novel Regulatory Models for Personalized CRISPR Treatments

Gene Therapy Leaders Explore Novel Regulatory Models for Personalized CRISPR Treatments

Gene Therapy Leaders Explore Novel Regulatory Models for Personalized CRISPR Treatments
Trendline Trendline
Eli Lilly Expands Oncology Portfolio with $2.3 Billion Acquisition of Ajax Therapeutics

Eli Lilly Expands Oncology Portfolio with $2.3 Billion Acquisition of Ajax Therapeutics

Eli Lilly Expands Oncology Portfolio with $2.3 Billion Acquisition of Ajax Therapeutics
Trendline Trendline
Berlin Heals' CMIC-III Study Shows Promising Results for Heart Failure Treatment

Berlin Heals' CMIC-III Study Shows Promising Results for Heart Failure Treatment

Berlin Heals' CMIC-III Study Shows Promising Results for Heart Failure Treatment
Trendline Trendline
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30 for Diabetes Treatment

Ascletis Completes Enrollment in U.S. Phase II Study of ASC30 for Diabetes Treatment

Ascletis Completes Enrollment in U.S. Phase II Study of ASC30 for Diabetes Treatment
Trendline Trendline
Intellia Therapeutics Begins FDA Submission for CRISPR-Based Hereditary Angioedema Treatment

Intellia Therapeutics Begins FDA Submission for CRISPR-Based Hereditary Angioedema Treatment

Intellia Therapeutics Begins FDA Submission for CRISPR-Based Hereditary Angioedema Treatment
Trendline Trendline
Mundipharma Reports Positive Results from Phase III Trial of Rezafungin for Fungal Disease Prevention

Mundipharma Reports Positive Results from Phase III Trial of Rezafungin for Fungal Disease Prevention

Mundipharma Reports Positive Results from Phase III Trial of Rezafungin for Fungal Disease Prevention
Rapid Read Rapid Read
Eskayef and Novo Nordisk Launch Local Insulin Production in Bangladesh

Eskayef and Novo Nordisk Launch Local Insulin Production in Bangladesh

Eskayef Pharmaceutical Limited and Novo Nordisk have initiated local production of modern insulin cartridges in Bangladesh, marking a significant step in improving diabetes care in the country. This collaboration involves technology transfer from Denmark and aims to reduce costs and increase access to insulin for millions of patients. The initiative includes an 18% price reduction on insulin products while maintaining international quality standards. The launch event, attended by Health Minister Sardar Shakhawat Hossain Bokul, emphasized the importance of local production of essential medicines. The project is part of a broader ambition to transform Bangladesh into a regional biotechnology manufacturing hub.
Trendline Trendline
U.S. Faces Challenges in Biotech Race Against China, Highlights Innovation and Regulatory Hurdles

U.S. Faces Challenges in Biotech Race Against China, Highlights Innovation and Regulatory Hurdles

U.S. Faces Challenges in Biotech Race Against China, Highlights Innovation and Regulatory Hurdles